Logo image of TEM

TEMPUS AI INC (TEM) Stock Fundamental Analysis

NASDAQ:TEM - Nasdaq - US88023B1035 - Common Stock - Currency: USD

68.09  -8.63 (-11.25%)

After market: 68.1 +0.01 (+0.01%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TEM. TEM was compared to 57 industry peers in the Life Sciences Tools & Services industry. The financial health of TEM is average, but there are quite some concerns on its profitability. TEM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TEM has reported negative net income.
In the past 5 years TEM always reported negative net income.
In the past 5 years TEM always reported negative operating cash flow.
TEM Yearly Net Income VS EBIT VS OCF VS FCFTEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

TEM has a worse Return On Assets (-82.40%) than 92.98% of its industry peers.
The Return On Equity of TEM (-1490.30%) is worse than 94.74% of its industry peers.
Industry RankSector Rank
ROA -82.4%
ROE -1490.3%
ROIC N/A
ROA(3y)-52.03%
ROA(5y)-45.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TEM Yearly ROA, ROE, ROICTEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200

1.3 Margins

TEM has a better Gross Margin (53.18%) than 63.16% of its industry peers.
TEM's Gross Margin has improved in the last couple of years.
TEM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.16%
GM growth 5YN/A
TEM Yearly Profit, Operating, Gross MarginsTEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 50 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

TEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TEM remains at a similar level compared to 1 year ago.
The debt/assets ratio for TEM is higher compared to a year ago.
TEM Yearly Shares OutstandingTEM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
TEM Yearly Total Debt VS Total AssetsTEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 3.65 indicates that TEM is not in any danger for bankruptcy at the moment.
The Altman-Z score of TEM (3.65) is better than 68.42% of its industry peers.
A Debt/Equity ratio of 8.17 is on the high side and indicates that TEM has dependencies on debt financing.
TEM has a worse Debt to Equity ratio (8.17) than 94.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.17
Debt/FCF N/A
Altman-Z 3.65
ROIC/WACCN/A
WACC11.25%
TEM Yearly LT Debt VS Equity VS FCFTEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 2.69 indicates that TEM has no problem at all paying its short term obligations.
With a Current ratio value of 2.69, TEM perfoms like the industry average, outperforming 43.86% of the companies in the same industry.
TEM has a Quick Ratio of 2.55. This indicates that TEM is financially healthy and has no problem in meeting its short term obligations.
TEM's Quick ratio of 2.55 is in line compared to the rest of the industry. TEM outperforms 50.88% of its industry peers.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.55
TEM Yearly Current Assets VS Current LiabilitesTEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.69% over the past year.
The Revenue has grown by 65.85% in the past year. This is a very strong growth!
Measured over the past years, TEM shows a very strong growth in Revenue. The Revenue has been growing by 41.43% on average per year.
EPS 1Y (TTM)20.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15%
Revenue 1Y (TTM)65.85%
Revenue growth 3Y41.43%
Revenue growth 5YN/A
Sales Q2Q%32.98%

3.2 Future

TEM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.83% yearly.
Based on estimates for the next years, TEM will show a very strong growth in Revenue. The Revenue will grow by 33.56% on average per year.
EPS Next Y-107.02%
EPS Next 2Y25.59%
EPS Next 3Y27.83%
EPS Next 5YN/A
Revenue Next Year32.36%
Revenue Next 2Y37.47%
Revenue Next 3Y33.56%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
TEM Yearly Revenue VS EstimatesTEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
TEM Yearly EPS VS EstimatesTEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TEM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TEM Price Earnings VS Forward Price EarningsTEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TEM Per share dataTEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6 -8

4.3 Compensation for Growth

TEM's earnings are expected to grow with 27.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.59%
EPS Next 3Y27.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TEM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEMPUS AI INC

NASDAQ:TEM (2/21/2025, 8:00:01 PM)

After market: 68.1 +0.01 (+0.01%)

68.09

-8.63 (-11.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-24 2025-02-24/amc
Inst Owners37.35%
Inst Owner Change32%
Ins Owners7.86%
Ins Owner Change-6.37%
Market Cap10.72B
Analysts80
Price Target59.77 (-12.22%)
Short Float %18.96%
Short Ratio1.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.09%
Min EPS beat(2)20.15%
Max EPS beat(2)52.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1%
Min Revenue beat(2)-0.22%
Max Revenue beat(2)2.21%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.48%
PT rev (3m)12.81%
EPS NQ rev (1m)4.17%
EPS NQ rev (3m)4.81%
EPS NY rev (1m)-4.65%
EPS NY rev (3m)-14.09%
Revenue NQ rev (1m)-1.58%
Revenue NQ rev (3m)-2.07%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-0.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.74
P/FCF N/A
P/OCF N/A
P/B 199.54
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.29
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4.07
BVpS0.34
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.4%
ROE -1490.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.18%
FCFM N/A
ROA(3y)-52.03%
ROA(5y)-45.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.16%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 8.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.69
Quick Ratio 2.55
Altman-Z 3.65
F-ScoreN/A
WACC11.25%
ROIC/WACCN/A
Cap/Depr(3y)71.18%
Cap/Depr(5y)77.03%
Cap/Sales(3y)5.6%
Cap/Sales(5y)10.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15%
EPS Next Y-107.02%
EPS Next 2Y25.59%
EPS Next 3Y27.83%
EPS Next 5YN/A
Revenue 1Y (TTM)65.85%
Revenue growth 3Y41.43%
Revenue growth 5YN/A
Sales Q2Q%32.98%
Revenue Next Year32.36%
Revenue Next 2Y37.47%
Revenue Next 3Y33.56%
Revenue Next 5YN/A
EBIT growth 1Y26.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.56%
EBIT Next 3Y30.93%
EBIT Next 5YN/A
FCF growth 1Y-33.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.43%
OCF growth 3YN/A
OCF growth 5YN/A